• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biochem Soc Trans . Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases

tetano

Editor, Senior Moderator
Biochem Soc Trans


. 2022 Jan 11;BST20211180.
doi: 10.1042/BST20211180. Online ahead of print.
Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases


Anoop Narayanan[SUP] 1 [/SUP], Shay A Toner[SUP] 1 [/SUP], Joyce Jose[SUP] 1 2 [/SUP]



Affiliations

Abstract

SARS-CoV-2, the coronavirus responsible for the current COVID-19 pandemic, encodes two proteases, 3CLpro and PLpro, two of the main antiviral research targets. Here we provide an overview of the structures and functions of 3CLpro and PLpro and examine strategies of structure-based drug designing and drug repurposing against these proteases. Rational structure-based drug design enables the generation of potent and target-specific antivirals. Drug repurposing offers an attractive prospect with an accelerated turnaround. Thus far, several protease inhibitors have been identified, and some candidates are undergoing trials that may well prove to be effective antivirals against SARS-CoV-2.

Keywords: 3CLpro; COVID-19; PLpro; SARS-CoV-2; antiviral; proteases.
 
Back
Top Bottom